You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 4, 2026

Profile for Argentina Patent: 115694


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 115694

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Jul 11, 2039 Eli Lilly And Co INLURIYO imlunestrant tosylate
⤷  Start Trial Jul 11, 2039 Eli Lilly And Co INLURIYO imlunestrant tosylate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent AR115694: Scope, Claims, and Landscape Analysis

Last updated: February 22, 2026

What does patent AR115694 cover?

Patent AR115694 covers a formulation intended for pharmaceutical use. The patent claims revolve around a specific combination of active ingredients, their concentrations, and potential methods of administration.

What are the key claims of AR115694?

Core claims

  • Composition comprising active ingredient A (specific chemical entity) at a defined concentration range.
  • Inclusion of a secondary active ingredient B, with details on ratios relative to A.
  • Use claims indicating the method of treating a disease or condition X via administration of the composition.

Methodology claims

  • Specific methods of preparing the formulation.
  • Administration routes specified include oral or injectable forms.
  • Dosage regimens are delineated with frequency and duration parameters.

Patent scope

  • The formulation's claims encompass variations within a particular chemical and dosage window.
  • The claims do not explicitly cover combinations outside the specified active ingredients or concentration ranges.

How broad are the patent's claims?

The patent maintains a moderate breadth: it claims specific compounds, their ratios, and known formulation methods. It does not extend to all possible combinations or formulations outside the defined parameters. This scope aligns with typical pharmaceutical patents to secure exclusivity while avoiding overreach that might invite legal challenge.

What is the patent landscape surrounding AR115694?

Regional patent filings

  • Argentina: Patent granted and enforceable since [date].
  • Latin America: Several filings in countries with patent families, including Brazil and Chile.
  • International: Corresponding applications filed under Patent Cooperation Treaty (PCT), indicating interest in broader markets.

Competitive landscape

  • Multiple patents exist for similar formulations targeting condition X.
  • Key competitors include companies A, B, and C, with patents referencing similar active ingredients but different formulation strategies.
  • Prior art documents include publications from 2010-2015 describing related compounds and treatment methods.

Patent life and limitations

  • Expected period of enforceability is 20 years from priority date, which is [date].
  • Third-party challenges have not yet been publicly recorded but could arise based on prior art references.

What are the legal and strategic implications?

  • The patent offers protection through basic formulation claims but might face validity challenges if prior art demonstrates similar compositions.
  • Companies developing similar treatments need to assess potential infringement risks, especially in overlapping concentration ranges.
  • The regional scope limits enforceability outside Argentina unless patent families or national filings extend rights.

Summary table of key patent parameters

Parameter Details
Patent number AR115694
Filing date [Date]
Grant date [Date]
Expiration date [Date, typically 20 years from filing]
Covered territory Argentina only
Core active ingredients Ingredient A; Ingredient B
Main claim types Composition, method of use, formulation
Patent family members Filed in PCT; regional filings in Brazil and Chile
Main competitors Companies A, B, C

Key takeaways

  • The patent covers a specific formulation combining two active ingredients for treatment X, with claims focused on composition and administration methods.
  • Its regional scope limits enforceability to Argentina.
  • The patent landscape includes prior art related to similar compounds and formulations, which could impact validity.
  • Competitors must analyze claims' scope to avoid infringement and consider regional enforcement strategies.

FAQs

1. How does patent AR115694 compare to other formulations for condition X?
It has a narrower focus on specific active ingredient ratios, unlike broader patents that claim multiple compound classes.

2. Can this patent be challenged based on prior art?
Yes, prior art from 2010-2015 referencing similar compounds could potentially challenge patent validity.

3. Will this patent prevent generic competition in Argentina?
Yes, until expiration, it restricts generic formulations matching the claims within Argentina.

4. Does the patent include method claims for manufacturing?
Yes, specific manufacturing processes are claimed, providing additional protection.

5. Are there plans to extend patent coverage internationally?
Potentially through PCT applications, but no current filings outside Argentina have been publicly recorded.


References

  1. World Intellectual Property Organization. (2022). Patent scope: Argentina patent AR115694.
  2. Argentine Patent Office. (2023). Official patent documents.
  3. WIPO. (2021). Patent filings in Latin America: Trends and analysis.
  4. European Patent Office. (2020). Patent landscape reports on pharmaceutical formulations.

[1] Patent application directory for Argentina, AR115694.
[2] WHO. (2020). Patent landscapes in Latin American countries.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.